Clinical interest of FDG-PET in head and neck cancers;Intérêt clinique de la TEP au 18FDG dans les cancers de la tête et du cou

Medecine Nucleaire

Volumn 25, Issue 6, 2001, Pages 315-323

  Paulus, Patrick ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

FDG; Head and neck cancer; Oncology; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER INVASION; CANCER LOCALIZATION; CANCER SCINTISCANNING; DIAGNOSTIC VALUE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; IMAGE QUALITY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW;

EID: 0035716428     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Head and neck
2. On the metabolism of tumors in the body
3. Enzymology of cancer cells
4. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
5. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: Potential method to differentiate malignancy from inflammation and normal uptake in the head and neck
6. The role of positron emission tomography in occultprimary head and neck cancers
7. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography
8. Occultprimary tumors of the head and neck. Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose
9. 18F-FDG whole body positron emission tomography in patient with unknown primary tumors
10. Metastatic head and neck cancer: Role and usefulness of FDG-PET in locating occult primary tumors
11. Detection of unknown primary head and neck tumors by positron emission tomography
12. Detection of unknown occult primary tumors using positron emission tomography
13. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer
14. 2(18F)-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck node manifestation
15. F-18-FDG-PET zur detektion des okkulten primärtumors bei patienten mith lymphknotenmetastasen der halsregion
16. Second respiratory and upper digestive tract cancer following oral squamous cell carcinoma: Oral oncology
17. Synchronous and metachronous head and neck carcinomas
18. FDG-PET in head and neck cancer
19. Fluorodeoxyglucose positron emission tomography, a new technique for increasing the detection rate of coincident thyroid cancer in the head and neck oncology
20. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography
21. Salivary gland tumors: Pretherapy evaluation with PET
22. Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI
23. The role of FDG-PET in the preoperative assessment of Nstaging in head and neck cancer
24. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinoma
25. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers
26. Positron emission tomography in the evaluation of the NO neck
27. Prospective comparison of 18F-FDG PET in lymph node staging of head and neck cancer
28. Preoperative evaluation of patients with primary head and neck cancer using dualhead 18fluorodeoxyglucose positron emission tomography
29. 18FDG-PET for the assessment of primary head and neck tumors. Clinical, CT and histopathological correlation in 38 patients
30. FDG-PET as a prognostic factor in high-grade astrocytoma
31. Preoperative evaluation of 54 gliomas by PET with fluroine-18-fluorodeoxyglucose and/or carbon-11 methionine
32. FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study
33. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
34. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's Disease and Non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
35. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer
36. Chemotherapeutic management of head and neck malignancies with PET
37. Positron emission tomography: An independent indicator of radiocurability in head and neck carcinomas
38. Therapy monitoring with 2-(18F)-FDG positron emission tomography after neoadjuvant radiation treatment of mouth carcinoma
39. Nuclear medicine in head and neck oncology: Reality and perspectives
40. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy2-(f-18)fluoro-D-glucose PET and MR imaging diagnosis
41. Can positron emission tomography distinguisch tumor recurrence from irradiation sequelae in patients treated for larynx cancer?
42. Head and neck cancer: Detection of recurrence with PET and2-(F18)fluoro-2-deoxy-D-glucose
43. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomaticpatient
44. Evaluation of chemotherapy response in patients with advanced head and neck cancer using FDG-PET
45. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography
46. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography
47. Early changes in fluorine 18-FDG uptake during radiotherapy
48. Chest wall FDG accumulation in serial FDG-PET imaging in patients being treated for bronchogenic carcinoma with radiation